Black Diamond Therapeutics Inc
BDTX2.859USD
+0.269+10.39%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
162.05MCap. mercado
31.83P/E TTM
Más Datos de Black Diamond Therapeutics Inc Compañía
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.
Información de la empresa
Símbolo de cotizaciónBDTX
Nombre de la empresaBlack Diamond Therapeutics Inc
Fecha de salida a bolsaJan 30, 2020
Director ejecutivoDr. Mark A. Velleca, M.D., Ph.D.
Número de empleados24
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
DirecciónOne Main Street, 14th Floor
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Teléfono16174175868
Sitio Webhttps://www.blackdiamondtherapeutics.com/
Símbolo de cotizaciónBDTX
Fecha de salida a bolsaJan 30, 2020
Director ejecutivoDr. Mark A. Velleca, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
77.15K
+8.69%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
22.52K
+32.52%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Mark A. Velleca, M.D., Ph.D.
Dr. Mark A. Velleca, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
77.15K
+8.69%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
22.52K
+32.52%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 2 de jul
Actualizado: mié., 2 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
18.29%
Versant Ventures
10.92%
Vestal Point Capital, LP
9.85%
New Enterprise Associates (NEA)
7.82%
Bellevue Asset Management AG
4.81%
Other
48.32%
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
18.29%
Versant Ventures
10.92%
Vestal Point Capital, LP
9.85%
New Enterprise Associates (NEA)
7.82%
Bellevue Asset Management AG
4.81%
Other
48.32%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
36.89%
Venture Capital
18.81%
Investment Advisor/Hedge Fund
18.59%
Hedge Fund
7.37%
Research Firm
1.43%
Individual Investor
0.96%
Bank and Trust
0.18%
Pension Fund
0.02%
Other
15.76%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
254
48.67M
85.58%
-26.49M
2025Q1
261
50.38M
88.73%
-26.95M
2024Q4
246
57.08M
100.88%
-16.52M
2024Q3
250
57.38M
101.59%
-12.76M
2024Q2
242
55.35M
99.47%
-3.18M
2024Q1
244
48.01M
92.96%
-13.90M
2023Q4
235
47.28M
91.68%
-8.00M
2023Q3
256
45.71M
88.75%
-9.85M
2023Q2
259
50.33M
103.17%
+16.38M
2023Q1
277
29.49M
80.76%
-7.91M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Investment Management, Inc.
10.40M
18.29%
-67.48K
-0.64%
Mar 31, 2025
Versant Ventures
6.21M
10.92%
-221.60K
-3.45%
Apr 11, 2025
Vestal Point Capital, LP
5.60M
9.85%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
4.45M
7.82%
--
--
Apr 11, 2025
Bellevue Asset Management AG
2.73M
4.81%
-5.78M
-67.91%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.36M
4.15%
-47.11K
-1.96%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.14%
-57.11K
-2.37%
Mar 31, 2025
Tang Capital Management, LLC
2.07M
3.64%
--
--
Mar 31, 2025
Millennium Management LLC
1.10M
1.94%
+545.84K
+97.81%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.05M
1.84%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Fidelity Enhanced Small Cap ETF
0.04%
iShares Micro-Cap ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Health Innovation Active ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Ver más
Fidelity Enhanced Small Cap ETF
Proporción0.04%
iShares Micro-Cap ETF
Proporción0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
iShares Health Innovation Active ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
DFA Dimensional US Core Equity Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
